urotherapy for patients with cancer

UROTHERAPY FOR PATIENTS WITH CANCER
Joseph Eldor, MD

Theoretical Medicine Institute
P.O.Box 12142, Jerusalem, 91120,Israel





Abstract

Cancer cells release various antigens, some of which appear
in the urine. Oral auto-urotherapy is suggested as a new
treatment modality for cancer patients. It will provide the
intestinal lymphatic system the many tumor antigens against
which antibodies may be produced. These antibodies may be
transpierced through the blood stream and attack the tumor
and its cells.


The philosophy of cancer

Microbes were known long before the germ theory of disease
was invented. It was not the discovery of germs that
revolutinized medicine, but the invention of a philosophy of
medical explanation that permitted germs to be causative
agents of disease (1).
Burnet and Thomas (2) postulated that specific cell
mediated immunity may have evolved in vertebrates
specially for defense against the "enemy within" rather than
against infecting microorganisms and parasites. Most human
cancers appear to lack truly tumor-specific antigens. The
same neoplastic cell can express several different tumor
antigens. For example, relatively cross-reacting
tumor-specific transplantation antigens have been
demonstrated in many chemically induced tumors (3).
Tumor-associated differentiation antigens are shared by
neoplastic and embryonic cells (4). The extent to which
human patients react immunologically against their cancers
has been a subject of much controversy (5).
Paul Ehrlich, in 1909, said:"I am convinced that during
development and growth malignant cells arise extensively
frequently but that in the majority of people they remain
latent due to the protective action of the host. I am also
convinced that this natural immunity is not due to the
presence of antimicrobial bodies but is determined purely by
cellular factors. These may be weakened in the older age
groups in which cancer is more prevalent" (6).


Tumor antigens in urine

Human melanoma cells express membrane antigens distinct from
those of the normal ectodermal counterparts (7).
Urinary-tumor-associated antigen (U-TAA) is one such
antigen. This high-molecular weight glycoprotein was first
described when melanoma urine was found to react with
autologous antibody (8). The antigen has since been detected
in the urine of 68% of melanoma patients. In addition, high
levels of U-TAA are found to correlate positively with
disease occurrence in surgically treated patients (9).
Prostatic specific antigen (PSA) has become an important
laboratory test in the management of prostate cancer. PSA
levels can be as readily obtained from voided urine as from
serum samples (10).
Quantitative urinary immunocytology with monoclonal antibody
(mab) 486p 3/12 proved to be valuable for diagnostic use in
bladder-cancer patients` urine, especially in the followup
of patients with superficial bladder carcinoma (11).
Quantitative urinary immunocytology is a general tool to
test the diagnostic usefulness of mabs, assuming that normal
and malignant cells differ in their quantitative expression
of a given antigen. Selective criteria for selecting mabs
for diagnostic approaches should ask not for tumor
specificity, but for different quantitative expression of
antigen in the tissues or cells in question.
Gastric juice oncofetal antigen determination, due to direct
shedding of antigens into the fluid around tumor tissues,
appears to accurately indicate the presence and degree of
gastric mucosal damage and to be to a slight extent
influenced by unrelated factors (12). Patients` age, for
example, modifies CEA serum levels (13). A monoclonal
antibody (mab) against a human colorectal adenocarcinoma
cell line has been raised (14), which reacts with
sialosylfucosyllactoteraose (15) corresponding to the
sialylated blood group antigen Lewis (a). The antigen
defined by this antibody, CA50, is elevated in the serum of
many patients with gastrointestinal tumors (16), with a
sensitivity for gastric cancer ranging from 20 (17) to 65%
(18). CA50 (a tumor-associated gangliosidic antigen) levels
have been determined by an RIA test in serum, gastric juice
and urine of patients undergoing upper gastrointestinal
tract endoscopy. Sensitivity and specificity were
respectively 23% and 89% for CA50 determination in urines
(19).
Soluble forms of membrane proteins such as cytokine
receptors or cellular adhesion molecules (CD14, TNF
receptor, CD25, IL-6 receptor, IFN-ç-receptor and CD54) have
been detected in human body fluids. They may have important
functions in immune regulation by blocking receptor/ligand
interactions. The human adhesion receptor CD58 (LFA-3) is
expressed on most cell types. A soluble form of CD58 (sCD58)
was purified from human urine and partially purified from
supernatant of the Hodgkin-derived cell line L428 (20).
Urinary organ-specific neoantigen from colorectal cancer
patients has been used to make a monoclonal antibody, BAC
18.1 (21). Organ-specific neoantigen originates in the colon
and is excreted into the urine, so the BAC 18.1 binding
levels in the urine may be a diagnostic aid for colorectal
cancer.
The polyamines spermidine, spermine and their diamine
precursor putrescine are ubiquitous constituents of
mammalian cells that are fundamentally involved in normal,
malignant and induced proliferative states. The polyamines
and ornithine decarboxylase (ODC), the rate-limiting enzyme
of the polyamine metabolism, were found to play an important
role in tumor promotion (22). The suggestion that polyamines
play an important role in colorectal cancer was confirmed by
studies that found elevated polyamine concentrations in
blood or urine (23) of patients with colon carcinoma.
Sensitivity of urinary polyamines for colon cancer were
highest for total spermidine (92.1%), acetylated putrescine
(84.5%), total putrescine (84.0%), N1-acetylspermidine
(79.3%) and N8-acetylspermidine (78.6%), but in all these
cases specificity was lower than 65% (24). In patients with
successful curative surgical treatment all preoperatively
elevated urinary polyamine concentrations markedly decreased
and returned to normal, whereas they were elevated and
increased further in patients with proven relapse of the
tumor and/or metastases in different organs (24).
The function of the CD44 gene is severely damaged, beginning
with the very early pre-invasive stages of tumor
development. This can be used as a means of tumor detection
and diagnosis both on solid tissue specimens (25) and on
exfoliated cells in clinically obtained excreta and body
fluids (26). Urine cell lysates obtained from patients with
bladder cancer can be discriminated from normal urine
lysates (27) using Western blotting with a monoclonal
antibody against the standard form of the CD44 protein.


Immunotherapy

Zbar and Tanaka (28) first reported on animal immunotherapy
based on the principle that tumor growth is inhibited at
sites of delayed hypersensitivity reactions provoked by
antigens unrelated to the tumor.They injected living
Mycobacterium bovis (strain BCG) into established
intradermal tumors and caused tumor regression and prevented
the development of metastases. For optimum therapeutic
effect contact between BCG and tumor cells was necessary.
The ability of tumor immune lymphocytes to localize
specifically to tumor offers a possibility for therapy which
has been utilized over the past several years (29).
The rejection of murine tumors expressing tumor-specific
transplantation antigens has been shown to be mediated
primarily by immune cells (30). Some 6 to 7% of transplant
recipients may develop cancer as a consequence of iatrogenic
immunosuppression (31).
Studies on the ability of patient lymphocytes to lyse tumor
cells in short term (2-8 hr) isotope release assays have
shown that lymphocytes from cancer patients can generally
destroy only tumor cells from the same patient (32-34),
unless the effector cells are not cytolytic T cells but, for
example, Natural Killer cells or Lymphokine Activated Killer
cells, in which case neoplastic cells representing many
different types are sensitive.
Immunotherapy is believed to be capable of eliminating only
relatively small amounts of neoplastic cells and, therefore,
the failure to induce a regression in patients with
excessive tumor burden is not unexpected (35,36). One
approach of immunotherapy is to "xenogenize" tumor cells by
virus infection. Another is to culture tumor infiltrating
lymphocytes with interleukin-2 and reinoculate them into the
host with cytokines (37). The introduction of recombinant
vectors expressing cytokine genes into tumor infiltrating
lymphocyte cells (38) or into the tumor cells themselves
(39) may enhance the migration of effector immune cells into
the tumor with consequent immunomediated control. The
considerable heterogeneity in the expression of tumor
associated differentiation antigens by cells within the same
tumor constitutes a problem for any immunotherapy, since it
facilitates the escape of antigen-negative tumor variants.
An alternative approach toward increasing the immune
response to tumor-associated differentiation antigens is to
treat the host to be immunized so as to abolish a
"suppressor" response. Such treatment can be provided in the
form of sublethal whole body x-irradiation (40), injection
of a drug such as cyclophosphamide (41), or by the
administration of certain anti-idiotypic antibodies (42).
Anergy is defined as a state of T lymphocyte
unresponsiveness characterized by absence of
proliferation,IL-2 production and diminished expression of
IL-2R (43,44). Most available data support suppression as a
mechanism of oral tolerance (45,46). Immunological
suppression is classically demonstrated by the suppression
of antigen-specific immune responses by T lymphocytes
(47,48).


Autoantigens

Oral administration of S-antigen (S-Ag), a retinal
autoantigen that induces experimental autoimmune uveitis,
prevented or markedly diminished the clinical appearance of
S-Ag-induced disease as measured by ocular inflammation
(49,50).
Gut associated lymphoid tissue has the capacity to generate
potent immune responses on one hand, and to induce
peripheral tolerance to external antigens on the other
(51-53). Both processes require antigen stimulation (53),
involve cytokine production (51) and might occur at the same
time - the first leading to potent local and systemic immune
responses, while the latter leads to systemic
antigen-specific nonresponsiveness (54). The generation of
acquired immune responses in the small intestine is believed
to occur in Peyer`s patches (51,55).
Orally fed protein antigens are found in the blood within 1
hr of feeding (56). Peripheral tolerance is not induced
locally, but rather is induced systemically upon transfer of
intact antigen, or its peptides, into the circulation
(57-59).Oral tolerance may be induced by a single feeding of
a protein antigen (60,61) or by several intermittent
feedings (46,62). In order to test whether feeding on
autoantigen could suppress an experimental autoimmune
disease, the Lewis rat model of experimental autoimmune
encephalomyelitis was studied (63). With increasing dosages
of GP-MBP, the incidence and severity of disease was
suppressed, as well as proliferative responses of lymph node
cells to MBP. Antibody responses to MBP were decreased but
not as dramatically as proliferative responses. Thus it
appears that oral tolerance to MBP, as to other non-self
antigens (45), preferentially suppress cellular immune
responses. It appears that homologous MBP is a more potent
oral tolerogen for experimental autoimmune encephalomyelitis
than heterologous MBP (64).
Tumor cells may escape immune recognition in immunocompetent
hosts by clonal evolution.Attention could be directed to
activate the resident immune effectors to break the anergy
or tolerance.


Urotherapy

Subcutaneous urine injections was practiced in 1912 by
Duncan (65) from New York under the name of auto-pyotherapy
for urinary infections, and in 1919 by Wildbolz (65) from
Bern for diagnostic purposes. Cimino (66) from Palermo
reported in 1927 on the use of auto uro-therapy for urinary
infections. Rabinowitch (67) in 1931 described this
auto-urine therapy for gonarthritis. Jausion et al. (68)
used this kind of therapy in 1933 for desensitization and
endocrinological problems. They treated with auto urotherapy
injections patients who suffered from migraine, pruritus,
asthma, urticaria, eczema, psoriasis, etc. Day (69)in 1936
treated patients with acute and subacute glomerulonephritis
by injection of an autogenous urinary extract. Sandweiss,
Saltzstein and Farbman (70) reported in 1938 that an extract
from urine of pregnant women has a prophylactic and
therapeutic effect on experimental ulcers in dogs. Shortly
thereafter the same group noted that an extract from urine
of normal women has a similar beneficial effect (71).
In 1926 Seiffert first described the construction of ileal
loop conduits for urinary diversion (72). Bricker in the
1950s popularized the use of the ileal loop as a means of
supravesical urinary diversion following exenteration for
pelvic malignancy in adults (73). Ureterosigmoidostomy as a
means of urinary diversion was used widely from 1920 to
1955. It was this type of implant which Hammer first
reported in 1929 associated with tumor (74).
Peyer`s patches are immunocompetent lymphoid organs which
participate in intestinal immune responses (75). Epithelial
cells within the crypts of the small bowel are one of the
fastest dividing cells in the body and yet they show one of
the lowest rate of malignant transformation (76). Stem cells
in the mucosa of the small bowel can divide every 8 to 12
hours (77). Tapper and Folkman (78) demonstrated that
exposure of intestinal segments to urine causes marked
lymphoid depletion in the segments. These studies give
additional support to the idea that a lymphocyte suppressive
factor exist in urine (79). The continued presence of urine
bathing the intestinal mucosa appears to locally inhibit
regeneration of the Peyer`s patches.
Starkey et al. (80) detected in human urine a material that
is biologically and immunologically similar to epidermal
growth factor that causes proliferation and keratinization
of epidermal tissues.
The increased susceptibility of the colon to cancer
associated with the existence of an implanted ureter has
been theorized to relate to 3 factore: 1. The role of the
urine in the colon (81,82). 2. The mechanical effect of the
fecal stream on the stoma (83). 3. The age of the
anastomosis (84). Adenocarcinoma of the colon mucosa is a
recognized complication of ureterosigmoidostomy. The tumor,
which develops adjacent to the junction of the ureter with
the bowel, occurs 500 times as often as in the population at
large and, in children so operated , 7,000 times as often as
in all persons under age 25. The latency period is 5 to 50
years (81,85-87).
It is common knowledge that malignant tumors may disappear
spontaneously although very infrequently (88-90). Usually it
is accepted that this could be due at least partly to an
immunological reaction (91,92). Renal adenocarcinoma is one
of the cancer types in which such spontaneous regressions
have been described most frequently (88,90).
Urinary extracts from patients with aplastic anemia (93) and
idiopathic thrombocytopenic purpura (94) are capable of
stimulating megakaryocyte colony growth in culture, and when
injected into rats could also induce thrombocytosis in
peripheral blood and megakaryocytosis in the spleens of
these animals. Stanley et al. (95) demonstrated that rabbits
immunized with human urine concentrates from leukemic
patients developed antibody which neutralized the mouse bone
marrow colony stimulating factor in human urine and human
serum.


Preconclusion

Henry Sigerist said, more than 50 years ago:"I personally
have the feeling that the problem of cancer is not merely a
biological and laboratory problem, but it belongs to a
certain extent to the realm of philosophy... All experiments
require certain philosophical preparation. And I have the
feeling that in the case of cancer many experiments were
undertaken without the necessary philosophical background,
and therefore proved useless" (96).


Conclusion

Urotherapy is suggested as a new kind of immunotherapy for
cancer patients. Unlike the clonal immunotherapy the urine
of the cancer patients contain the many tumor antigens which
constitute the tumor. Oral auto-urotherapy will provide the
intestinal lymphatic system the tumor antigens against which
they may produce antibodies due to non-self recognition.
These antibodies may be transpierced through the blood
stream and attack the tumor and its cells.


References

1. Root-Bernstein RS. Causality, complementarity, evolution,
and emergent properties. In Iversen OH (ed.):New Frontiers
in Cancer Causation. Taylor & Francis 1993, p.1-14
2. Burnet FM. The concept of immunological surveillance.
Prog Exp Tumor Res 1970;13:1-27
3. Hellstrom I, Hellstrom KE, Zeidman L, Bernstein ID, Brown
JP. Cell-mediated reactivity to antigens shared by Moloney
virus induced lymphoma cells (LSTRA) and cells from certain
3-methylcholanthrene induced mouse sarcomas. Int J Cancer
1979;23:555-64
4. Hellstrom I, Hellstrom KE, Shepard TH. Cell-mediated
immunity against antigens common to tumor colonic carcinomas
and fetal gut epithelium. Int J Cancer 1970;6:346-51
5. Hellstrom KE, Hellstrom I. Immunological approach to
tumor therapy: Monoclonal antibodies, tumor vaccines, and
anti-idiotypes. In Covalently Modified Antigens and
Antibodies in Diagnosis and Therapy. Vol.2. Edited by Quash
GA, Rodwell JD. Marcel Dekker, Inc., New York 1989, p.1
6. Ehrlich P. In Himmelweit S., ed. The Collected Papers of
Paul Ehrlich (translated by P. Alexander). Pergamon Press,
Oxford, 1957
7. Watanabe T, Punkel CS, Takeyama H, Lloyd KO, Shiku H, Li
LTC, Travassos LR, Oettgen HF, Old LJ. Human melanoma
antigen AH is an autologous ganglioside related to GD2. J
Exp Med 1982;156:1884-9
8. Rote NS, Gupta RK, Morton DL. Tumor-associated antigens
detected by autologous sera in urine of patients with solid
neoplasms. J Surg Res 1980;29:18-22
9. Gupta RK, Huth JF, Korn EL, Morton DL. Prognostic
significance of urinary antigen analysis by enzyme-linked
immunosorbant assay in melanoma patients. Diag Immunol
1983;1:303-309
10. DeVere White RW, Meyers FJ, Soares SE, Miller OG,
Soriano TF. Urinary prostate specific antigen levels: Role
in monitoring the response of prostate cancer to therapy. J
Urol 1992;147:947-951
11. Huland E, Huland H, Meier T, Baricordi O, Fradet Y,
Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ.
Comparison of 15 monoclonal antibodies against
tumor-associated antigens of transitional cell carcinoma of
the human bladder. J Urol 1991;146:1631-6
12. Farinati F, Cardin F, Costa F, Nitti D, Di Mario F,
Naccarato R. Gastric juice CEA levels: importance of age and
gastric mucosal damage. Europ J Cancer Clin Oncol
1986;22:527-9
13. Touitou Y, Proust J, Klinger E, Nakache JP, Huard D,
Sachet A. Cumulative effects of age and pathology on plasma
carcinoembryonic antigen in an unselected elderly
population. Europ J Cancer Clin Oncol 1984;20:369-374
14. Lindholm L, Holmgren J, Svennerholm L, Fredman P,
Nillson O, Persson P, Myrvold H, Lagergard T. Monoclonal
antibodies against gastro-intestinal tumor-associated
antigens isolated as monosialogangliosides. Int Arch Allergy
appl Immun 1983;71:178-181
15. Mansson JE, Fredman P, Nilsson O, Lindholm L, Holmgren
J, Svennerholm C. Chemical structure of carcinoma
ganglioside antigens defined by monoclonal antibody CA50 and
some allied gangliosides of human pancreatic adenocarcinoma.
Biochim Biophys Acta 1985;834:110-117
16. Holmgren J, Lindholm L, Persson B, Lagergard T, Nilsson
O, Svennerholm L, Rudenstam CM, Unsgaard B, Yngvason F,
Pettersson S, Killander AF. Detection by monoclonal antibody
of carbohydrate antigen CA50 in serum of patients with
carcinoma. Brit Med J 1984;288:1479-1482
17. Dienst C, Clodius T, Oldorp T, Uhlenbruch G, Diehl V. CA
19-9, CA50 und CEA bei Pankreas und gastrointestinal
Tumoren. Medizin Klin 1987;82:45-50
18. Bruhn HD, Broers H, Euler H, Everding A, Feller AC,
Hedderich J, Jostarndt L, Joob B, Zurborn KH, Loffler H. CA
50 im serum von Karzinom-Patienten. Deutsch Med Wochensch
1986;34:1267-1272
19. Farinati F, Holmgren J, Di Mario F, Cardin F, Valliante
F, Fanton MC, Della Libera G, Nitti D, Plebani M, Crestani
B, Naccarato R. CA 50 determination in body fluids: Can we
screen patients at risk for gastric cancer? Int J Cancer
1991;47:7-11
20. Hoffmann JC, Dengler TJ, Knolle PA, Albert-Wolf M, Roux
M, Wallich R, Meuer SC. A soluble form of the adhesion
receptor CD58 (LFA-3) is present in human body fluids. Eur J
Immunol 1993;23:3003-3010
21. Tobi M, Darmon E, Rozen P, Harpaz N, Fink A, Maliakkal
B, Halline A, Mobarhan S, Bentwich Z. Urinary organ specific
neoantigen. A potentially diagnostic test for colorectal
cancer. Dig Dis Sci 1995;40:1531-7
22. Boutwell RK. Evidence that an elevated level of
ornithine decarboxylase activity is an essential component
of tumor promotion. Adv Polyamine Res 1983;4:127-133
23. lipton A, Sheehan L, Harvey HA. Urinary polyamine levels
in patients with gastrointestinal malignancy. Cancer
1975;36:2351-4
24. Loser C, Folsch UR, Paprotny C, Creutzfeldt W.
Polyamines in colorectal cancer. Evaluation of polyamine
concentrations in the colon tissue, serum and urine of 50
patients with colorectal cancer. Cancer 1990;65:958-966
25. Matsumura Y, Tarin D. Significance of CD44 gene products
for cancer diagnosis and disease evaluation. Lancet
1992;340:1053-8
26. Matsumura Y, Hanbury D, Smith JC, Tarin D. Non-invasive
detection of malignancy by identification of unusual CD44
gene activity in exfoliated cancer cells. Br Med J
1994;308:619-624
27. Matsumura Y, Sugiyama M, Matsumura S, Hayle AJ, Robinson
P, Smith JC, Tarin D. Unusual retention of introns in CD44
gene transcripts in bladder cancer provides new diagnostic
and clinical oncological opportunities. J Pathol
1995;177:11-20
28. Zbar B, Tanaka T. Immunotherapy of cancer: regression of
tumors after intralesional injection of living Mycobacterium
bovis. Science 1971;172:271-273
29. Rosenberg SA, Packard BS, Aebersold PM et al. Use of
tumor-infiltrating lymphocytes and interleukin-2 in the
immunotherapy of patients with metastatic melanoma. A
preliminary report. N Engl J Med 1988;319:1676-80
30. Hellstrom KE, Hellstrom I. Cellular immunity against
tumor specific antigens. Adv Cancer Res 1969;12:167-223
31. Penn I. Tumors of the immunocompromised patient. Ann Rev
Med 1988;39:63-73
32. Vanky F, Klein E, Willems J et al. Lysis of autologous
tumor cells by blood lymphocytes activated in autologous
mixed lymphocyte tumor cell culture - no correlation with
the postsurgical clinical course. Cancer Immunol Immunother
1987;24:180
33. Vanky F, Klein E. Specificity of auto-tumor cytotoxicity
exerted by fresh, activated and propagated human T
lymphocytes. Int J Cancer 1982;29:547
34. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum
Buschenfelde KH. Cytolytic T cell clones against an
autologous human melanoma: Specificity study and definition
of three antigens by immunoselection. Proc Natl Acad Sci
(USA) 1989;86:2804-8
35. LoBuglio AF, Neidhart JA. A review of transfer factor
immunotherapy in cancer. Cancer 1974;34:1563-70
36. Levin AS, Byers VS, Fudenberg HH, Wybran J, Hackett AJ,
Johnston JO, Spitler LE. Osteogenic sarcoma. Immunologic
parameters before and during immunotherapy with
tumor-specific transfer factor. J Clin Invest 1975;55:487-99
37. Rosenberg SA, Schearz SL, Speiss PJ. Combination
immunotherapy for cancer: synergistic antitumor interactions
of interleukin-2, alpha interferon and tumor-infiltrating
lymphocytes. JNCI 1988;80:1393-1397
38. Rosenberg SA, Aebersold P, Cornetta K et al. Gene
transfer into humans: immunotherapy of melanoma using
tumor-infiltrating lymphocytes modified by retroviral gene
transduction. N Engl J Med 1990;323:570-578
39. Russell SJ, Eccles SA, Fleming CL, Johnson CA, Collins
MKL. Decreased tumorigenicity of a transplantable rat
sarcoma following transfer and expression of an IL-2 cDNA.
Int J Cancer 1991;47:244-252
40. Hellstrom KE, Hellstrom I, Kant JA, Tamerius JD.
Regression and inhibition of sarcoma growth by interference
with a radiosensitive T cell population. J Exp Med
1978;148:799-804
41. Estin CD, Stevenson US, Hellstrom I, Hellstrom KE.
Cyclophosphamide potentiates the antitumor activity of
v-p97NY. Cell Immunol 1989;120:126-31
42. Nepom GT, Hellstrom KE. Anti-idiotypic antibodies and
the induction of specific tumor immunity. Cancer Metast Rev
1987;6:489-502
43. Schwartz RH. A cell culture model for T lymphocyte
clonal anergy. Science 1990;248:1349-1356
44. Jenkins MK, Schwartz RH. Antigen presentation by
chemically modified splenocytes induces antigen-specific T
cell unresponsiveness in vitro and in vivo. J Exp Med
1987;165:302-319
45. Mowat AM. The regulation of immune responses to dietary
protein antigens. Immunol Today 1987;8:93-98
46. Weiner HL, Zhang ZJ, Khoury SJ, Miller A, Al-Sabbagh A,
Brod SA, Lider O, Higgins P, Sobel R, Nussenblatt RB, Hafler
DA. Antigen-driven peripheral immune tolerance. Suppression
of organ-specific autoimmune diseases by oral administration
of autoantigens. Ann NY Acad Sci 1991;636:227-232
47. Sercarz E, Krzych U. The distinctive specificity of
antigen-specific suppressor T cells. Immunol Today
1991;12:111-118
48. Green DR, Flood PM, Gershon RK. Immunoregulatory T-cell
pathways. Annu Rev Immunol 1983;1:439-463
49. Thurau SR, Caspi RR, Chan CC, Weiner HL, Nussenblatt RB.
Immunological suppression of experimental autoimmune
uveitis. Fortschr Ophthalmol 1991;88:404-407
50. Nussenblatt RB, Caspi RR, Mahdi R, Chan CC, Roberge F,
Lider O, Weiner HL. Inhibition of S-antigen induced
experimental autoimmune uveoretinitis by oral induction of
tolerance with S-antigen. J immunol 1990;144:1689-1695
51. Brandtzaeg P. Overview of the mucosal immune system.
Curr top Microbiol Immunol 1989;146:13-28
52. MesteckyJ, McGhee JR. Oral immunization: Past and
present. Curr Top Microbiol Immunol 1989;146:3-12
53. Stokes CR. Induction and control of intestinal immune
responses. In Newby TJ, Stokes CR (eds.): Local immune
responses of the gut. Boca Raton, CRC Press, 1984,pp.97-142
54. Hanson DG, Vaz NM, Rawlings LA, Lynch JM. Inhibition of
specific immune responses by feeding protein antigens. II.
Effects of prior passive and active immunization. J Immunol
1979;122:2261-2266
55. Brandtzaeg P, Baklien K, Bjerke K, Rognum TO, Scott H,
Valnes K. Nature and properties of the human
gastrointestinal immune system. In Miller K, Nicklin S
(eds.):Immunology of the Gastrointestinal Tract. Boca Raton,
CRC Press, 1987, pp.1-88
56. Peng HJ, Turner MW, Strobel S. The generation of a
"tolerogen" after the ingestion of ovalbumin is
time-dependent and unrelated to serum levels of
immunoreactive antigen.Clin Exp Immunol 1990;81:510-515
57. Stokes CR, Swarbrick ET, Soothill JF. Genetic
differences in immune exclusion and partial tolerance to
ingested antigens. Clin Exp Immunol 1983;52:678-684
58. Swarbrick ET, Stokes CR, Soothill JF. Absorption of
antigens after oral immunization and the simultaneous
induction of specific systemic tolerance. Gut
1979;20:121-125
59. Miller A, Zhang AJ, Prabdu-Das M, Sobel A, Weiner HL.
Active suppression vs. clonal anergy following oral or IV
administration of MBP in actively and passively induced EAE.
Neurology 1992;42(Suppl 3):301
60. Lamont AG, Gordon M, Ferguson A. Oral tolerance in
protein deprived mice. II. Evidence of normal 'gut
processing' of ovalbumin, but suppressor cell deficiency, in
deprived mice. Immunology 1987;61:339-343
61. Hanson DG, Vaz NM, Maia LC, Hornbrook MM, Lynch JM, Roy
CA. Inhibition of specific immune responses by feeding
protein antigens. Int Arch Allergy Appl Immunol
1977;55:526-532
62. Matthews JB, Fivaz BH, Sewell HF. Serum and salivary
antibody responses and the development of oral tolerance
after oral and intragastric antigen administration. Int Arch
Allergy Appl Immunol 1981;65:107-113
63. Higgins P, Weiner HL. Suppression of experimental
autoimmune encephalomyelitis by oral administration of
myelin basic protein and its fragments. J Immunol
1988;140:440-445
64. Miller A, Lider O, Al-Sabbagh A, Weiner HL. Suppression
of experimental autoimmune encephalomyelitis by oral
administration of myelin basic protein. J Neuroimmunol
1992;39:243-250
65. Jausion H. Sur l'auto-ouro-therapie. Journal D'Urologie
1935;39:58-59
66. Cimino T. Premiers essais de vaccine-proteine-therapie
des infections non gonococciques ni tuberculeuses des voies
urinaires a l'aide des injections sous-cutanees de l'urine
purulente du sujet, sterilisee par l'ebullition
(ouro-therapie). Rivista Sanitaria 1927;186
67. Rabinowitch IM. Auto-urine-therapy in gonarthritis.
Vratchebnaia gazeta 1931;35:677-8
68. Jausion H, Giard R, Martinaud G. L'auto-ouro-therapie.
La Presse Medicale 1933;76:1467-1470
69. Day HB. Treatment of glomerulonephritis by antigen.
Lancet 1936;1456-9
70. Sandweiss DJ, Saltzstein HC, Farbman AA. The prevention
or healing of experimental ulcer in Mann-Williamson dogs
with the Anterior-Pituitary-Like hormone (Antuitrin-S). Am J
Dig Dis 1938;5:24-30
71. Sandweiss DJ, Saltzstein HC, Farbman AA. The relation of
sex hormones to peptic ulcer. Am J Dig Dis 1939;6:6-12
72. Seiffert L. Die "Darn-Siphonblase". Arch fur Klin Chir
1935;183:569
73. Bricker EM. Bladder substitution after pelvic
evisceration. Surg Clin North Am 1950;30:1511
74. Hammer E. Cancer du colon sigmoide dix ans apres
implantation des ureteres d'une vessie exstrophiee. J Urol
Nephrol 1929;28:260
75. Miller-Schoop JW, Good RA. Functional studies of Peyer`s
patches: Evidence for their participation in intestinal
immune responses. J Immunol 1975;144:1757
76. Barclay THC, Schapira DV. Malignant tumors of the small
bowel. Cancer 1983;51:878-881
77. Loeffler M, Stein R, Wichmann HE, Potten CS, Kaur P,
Chwalinski S. Intestinal cell proliferation. I. A
comprehensive model of steady-state proliferation in the
crypt. Cell Tissue Kinet 1986;19:627-645
78. Tapper D, Folkman J. Lymphoid depletion in ileal loops:
Mechanism and clinical implications. J Pediatr Surg
1976;11:871-880
79. Wilson WEC, Kirkpatrick CH, Talmage DW. Suppression of
immunologic responsiveness in uremia. Ann Intern Med
1965;62:1
80. Starkey RH, Cohen S, Orth DN. Epidural growth factor:
Identification of a new hormone in human urine. Science
1975;189:800-802
81. Urdaneta LF, Duffell D, Creevy CD, Aust JB. Late
development of primary carcinoma of the colon following
ureterosigmoidostomy: report of three cases and literature
review. Ann Surg 1966;164:503-13
82. Harguindey SS, Colbeck RC, Bransome ED JR.
Ureterosigmoidostomy and cancer: new observations (letter).
Ann Intern Med 1975;83:833
83. Rivard JY, Bedard A, Dionne L. colonic neoplasms
following ureterosigmoidostomy. J Urol 1975;113:781-6
84. Carswell JJ III, Skeel DA, Witherington R, Otken LB Jr.
Neoplasia at the site of ureterosigmoidostomy. J Urol
1976;115:750-2
85. Lasser A, Acosta AE. colonic neoplasms complicating
ureterosigmoidostomy. Cancer 1975;35:1218-22
86. Sooriyaarachchi GS, Johnson RO, Carbone PP. Neoplasms of
the large bowel following ureterosigmoidostomy. Arch Surg
1977;112:1174-7
87. Eraklis AJ, Folkman MJ. Adenocarcinoma at the site of
ureterosigmoidostomies for exstrophy of the bladder. J
Pediatr Surg 1978;13:730-4
88. Everson T. Spontaneous regression of cancer. Ann NY Acad
Sci 1964;114:721-35
89. Stephenson H, Delmez J, Renden D, Kimpton R, Todd P,
Charron T, Lindberg D. Host immunity and spontaneous
regression of cancer evaluated by computerized data
reduction study. Surg Gynecol Obstet 1971;133:649-55
90. Cole W. Spontaneous regression of cancer: The metabolic
triumph of the host? Ann NY Acad Sci 1974;230:111-41
91. Burnet F. Immunological aspects of malignant disease.
Lancet 1967;II:1171-4
92. Droller M. Immunotherapy and genitourinary neoplasia.
Urol Clin N Am 1980;7:831-46
93. Enomoto K, Kawakita M, Kishimoto S, Katayama N, Miyake
T. Thrombopoiesis and megakaryocyte colony stimulating
factor in the urine of patients with aplastic anemia. Br J
Haematol 1980;45:551-556
94. Kawakita M, Enomoto K, Katayama N, Kishimoto S, Miyake
T. Thrombopoiesis and megakaryocyte colony stimulating
factors in the urine of patients with idiopathic
thrombocytopenic purpura. Br J Haematol 1981;48:609-615
95. Stanley ER, McNeill TA, Chan SH. Antibody production to
the factor in human urine stimulating colony formation in
vitro by bone marrow cells. Br J Haematol 1970;18:585-590
96. Galdston I. The ideological basis of discovery. Bull
Hist Med 1939;7:729-735


Tweet